Navigation Links
InterMune to Present at Bank of America Merrill Lynch Health Care Conference
Date:5/4/2011

BRISBANE, Calif., May 4, 2011 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Bank of America Merrill Lynch 2011 Health Care Conference in Las Vegas, NV on May 11, 2011, at 1:00 p.m. PDT.  

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com.  The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology.  InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections.  The pulmonology portfolio includes Esbriet® (pirfenidone), which is now approved in the European Union for the treatment of adults with mild to moderate IPF, a progressive and fatal lung disease.  The hepatology portfolio includes next-generation HCV protease inhibitor and NS5A research programs.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. InterMune Reports First Quarter 2011 Financial Results and Business Highlights
2. InterMune to Release First Quarter Financial Results on April 28
3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 16
4. InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbrietâ„¢ (Pirfenidone) in Europe
5. InterMune to Release Third Quarter Financial Results on October 28
6. InterMune Sells Danoprevir Rights to Roche for $175 Million
7. InterMune to Present at 2010 Citi Health Care Conference
8. InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application
9. InterMune to Release First Quarter Financial Results on April 29
10. InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF
11. InterMune Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... LOS ANGELES, Calif. (PRWEB) , ... April 27, ... ... Los Angeles office of Lewis Roca Rothgerber Christie LLP as an associate in ... and prosecuting U.S. and international electrical, mechanical and electromechanical patent applications. He has ...
(Date:4/26/2016)... ... 2016 , ... Heidelberg Instruments, a leader in design, development ... Volume Pattern Generator (VPG) line of lithography systems. The breakthrough VPG+ system is ... a solution for mid volume direct write lithography applications. It utilizes the ...
(Date:4/26/2016)... ... 26, 2016 , ... BioFactura, Inc ., a biopharmaceutical research and manufacturing ... Healthy investor interest drove significant oversubscription of the original $1.5M target. The funds ... the advanced preclinical stages. , Chief Executive Officer and President, Darryl Sampey ...
(Date:4/26/2016)... ... ... uBiome, the leading microbial genomics company, welcomes Neil Grimmer, Co-founder and Chairman ... co-founding Plum in 2007, Neil Grimmer was Vice President of Strategy and Innovation at ... of ideas, products, and brands, Grimmer has been at the forefront of launching more ...
Breaking Biology Technology:
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
(Date:3/18/2016)... March 18, 2016 --> ... Biometrics, ICT, Manned & Unmanned Vehicles, Physical infrastructure and Perimeter ... companies in the border security market and the continuing migration ... Europe has led visiongain to publish ... success. --> defence & security companies in ...
(Date:3/15/2016)... JERUSALEM , March 15, 2016 ... Jerusalem , the technology-transfer company of the Hebrew University, ... developer of remote sensing technology of various human biological ... funding, raising $2.0 million from private investors. ... technology, based on the detection of electromagnetic emissions from ...
Breaking Biology News(10 mins):